{"organizations": [], "uuid": "22354aebc2ab7dcf66e05fd2ed1b59321957fac7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aptose-biosciences-announces-licen/brief-aptose-biosciences-announces-license-agreement-for-dual-bet-kinase-targeting-program-with-ohm-oncology-idUSFWN1QP0JW", "country": "US", "domain_rank": 408, "title": "BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology ‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-03-07T20:15:00.000+02:00", "replies_count": 0, "uuid": "22354aebc2ab7dcf66e05fd2ed1b59321957fac7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aptose-biosciences-announces-licen/brief-aptose-biosciences-announces-license-agreement-for-dual-bet-kinase-targeting-program-with-ohm-oncology-idUSFWN1QP0JW", "ord_in_thread": 0, "title": "BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology ‍​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "aptose biosciences inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "ohm", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Aptose Biosciences Inc:\n* APTOSE BIOSCIENCES INC - ‍​\n* APTOSE BIOSCIENCES - ‍ AGREEMENT PROVIDES OHM ONCOLOGY RIGHTS FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF APL-581\n* APTOSE BIOSCIENCES - TO RETAIN REACQUISITION RIGHTS TO CERTAIN MOLECULES, OHM TO HAVE RIGHTS TO DEVELOP, SUBLICENSE OTHER MOLECULES.​\n* APTOSE BIOSCIENCES - ‍UNDER AGREEMENT, CO TO RECEIVE NOMINAL UPFRONT CASH PAYMENT, ELIGIBLE FOR UP TO $125 MILLION ADDITIONAL PAYMENTS BASED ON MILESTONES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T20:15:00.000+02:00", "crawled": "2018-03-08T17:26:22.000+02:00", "highlightTitle": ""}